A $123M Flare will get Third Rock on­col­o­gy biotech in­to the clin­ic this year

Flare Ther­a­peu­tics will start its first hu­man tri­al this year with an in­ves­ti­ga­tion­al urothe­lial can­cer drug af­ter pulling to­geth­er a $123 mil­lion Se­ries B from Big Phar­mas, VCs and its in­cu­ba­tor, Third Rock Ven­tures.

Launched in 2021 on the idea that a biotech could fi­nal­ly suc­ceed at drug­ging the much-sought-af­ter but stub­born tran­scrip­tion fac­tor, Flare Ther­a­peu­tics said Wednes­day it is now primed for the clin­ic af­ter clos­ing its large fi­nanc­ing haul ear­li­er this year. The raise is a rel­a­tive­ly stark fig­ure in a tough start­up fi­nanc­ing en­vi­ron­ment but fur­ther buoys the up­beat sig­nals com­ing out of oth­er Third Rock biotechs in re­cent weeks, in­clud­ing the $200 mil­lion CAR­GO Ther­a­peu­tics and $100 mil­lion Rap­port Ther­a­peu­tics rounds.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER